Serum markers of microbial translocation and intestinal damage in assessment of gastrointestinal tract involvement in systemic sclerosis.
Humans
Female
Scleroderma, Systemic
/ blood
Middle Aged
Male
Biomarkers
/ blood
Bacterial Translocation
Adult
Haptoglobins
/ analysis
Aged
Cholera Toxin
/ blood
Interleukin-6
/ blood
Protein Precursors
/ blood
Severity of Illness Index
Fatty Acid-Binding Proteins
/ blood
Carrier Proteins
/ blood
Acute-Phase Proteins
Immunoglobulin M
/ blood
Gastrointestinal Tract
/ microbiology
Gastrointestinal Diseases
/ blood
Dysbiosis
/ blood
Membrane Glycoproteins
Gastrointestinal
LBP
Microbial translocation
Systemic sclerosis
UCLA
Zonulin
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
19 Sep 2024
19 Sep 2024
Historique:
received:
04
07
2024
accepted:
14
08
2024
medline:
19
9
2024
pubmed:
19
9
2024
entrez:
18
9
2024
Statut:
epublish
Résumé
Gastrointestinal (GI) tract involvement affects up to 90% of Systemic sclerosis (SSc) patients. The presence of GI symptoms is assessed by the University of California, Los Angeles, and Scleroderma Clinical Trials Consortium Gastrointestinal Scale (UCLA SCTC GIT 2.0). Microbial translocation (MT) is reported in SSc patients consequently to increased intestinal permeability due to intestinal damage (ID) and dysbiosis. Aim of this study was to assess circulating levels of LBP and EndoCab IgM (markers of MT), IL-6 (marker of inflammation), I-FABP and Zonulin (markers of ID) in a cohort of SSc patients and healthy controls (HC). Moreover, we aimed to correlate these parameters with severity of GI symptoms. UCLA SCTC GIT 2.0 questionnaire was administered to 60 consecutive SSc patients. Markers of MT, inflammation and ID were evaluated in SSc patients and HC. SSc patients had higher median value of markers of MT, inflammation and ID than HC. The logistic regression analysis showed LBP as the only variable associated with an UCLA total score "moderate-to-very severe" [OR 1.001 (CI 95%: 1.001-1.002), p < 0.001]. The logistic regression analysis showed LBP [OR 1.002 (CI 95%: 1.001-1.003), p < 0.01] and disease duration [OR 1.242 (CI 95%: 1.023-1.506), p < 0.05] as variables associated with UCLA distension/bloating "moderate-to-very severe". The logistic regression analysis showed LBP as the only variable associated with UCLA diarrhea "moderate-to-very severe" [OR 1.002 (CI 95%: 1.001-1.003), p < 0.01]. SSc patients with dysregulation gut mucosal integrity expressed by high levels of MT and ID biomarkers had more severe GI symptoms.
Identifiants
pubmed: 39294494
doi: 10.1007/s10238-024-01466-1
pii: 10.1007/s10238-024-01466-1
doi:
Substances chimiques
Biomarkers
0
zonulin
0
Haptoglobins
0
Cholera Toxin
9012-63-9
Interleukin-6
0
Protein Precursors
0
Fatty Acid-Binding Proteins
0
lipopolysaccharide-binding protein
0
Carrier Proteins
0
Acute-Phase Proteins
0
Immunoglobulin M
0
FABP2 protein, human
0
Membrane Glycoproteins
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
225Informations de copyright
© 2024. The Author(s).
Références
Volkmann ER, Andréasson K, Smith V. Systemic sclerosis. Lancet. 2023;401(10373):304–18. https://doi.org/10.1016/S0140-6736(22)01692-0 .
doi: 10.1016/S0140-6736(22)01692-0
pubmed: 36442487
McMahan ZH, Kulkarni S, Chen J, Chen JZ, Xavier RJ, Pasricha PJ, Khanna D. Systemic sclerosis gastrointestinal dysmotility: risk factors, pathophysiology, diagnosis and management. Nat Rev Rheumatol. 2023;19(3):166–81. https://doi.org/10.1038/s41584-022-00900-6 .
doi: 10.1038/s41584-022-00900-6
pubmed: 36747090
Forbes A, Marie I. Gastrointestinal complications: the most frequent internal complications of systemic sclerosis. Rheumatology (Oxford). 2009;48(Suppl 3):36–9.
Schmeiser T, Saar P, Jin D, Noethe M, Müller A, Soydan N, Hardt PD, Jaeger C, Distler O, Roeb E, Bretzel RG, Müller Ladner U. Profile of gastrointestinal involvement in patients with systemic sclerosis. Rheumatol Int. 2012;32:2471–8.
doi: 10.1007/s00296-011-1988-6
pubmed: 21769490
Shreiner AB, Murray C, Denton C, Khanna D. Gastrointestinal manifestations of systemic sclerosis. J Scleroderma Relat Disord. 2016;1(3):247–56. https://doi.org/10.5301/jsrd.5000214 .
doi: 10.5301/jsrd.5000214
pubmed: 28133631
Khanna D, Hays RD, Maranian P, Seibold JR, Impens A, Mayes MD, et al. Reliability and validity of the university of California, Los Angeles scleroderma clinical trial consortium gastrointestinal tract instrument. Arthritis Rheum. 2009;61:1257–63. https://doi.org/10.1002/art.24730 .
doi: 10.1002/art.24730
pubmed: 19714600
pmcid: 2767193
Oliva A, Aversano L, De Angelis M, Mascellino MT, Miele MC, Morelli S, Battaglia R, Iera J, Bruno G, Corazziari ES, Ciardi MR, Venditti M, Mastroianni CM, Vullo V. Persistent systemic microbial translocation, inflammation, and intestinal damage during clostridioides difficile infection. Open Forum Infect Dis. 2019;7(1):507. https://doi.org/10.1093/ofid/ofz507 .
doi: 10.1093/ofid/ofz507
Bruno G, Gagliardi A, Oliva A, Trancassini M, Macone A, Cicerone C, D’Abramo A, Iebba V, Auria S, Bonfiglio G, Zingaropoli MA, D’Ettorre G, Badiali D, Vullo V, Corazziari ES, Schippa S. Fecal microbial transplantation impact on gut microbiota composition and metabolome, microbial translocation and T-lymphocyte immune activation in recurrent clostridium difficile infection patients. New Microbiol. 2019;42(4):221–4.
pubmed: 31609455
Oliva A, Miele MC, Di Timoteo F, De Angelis M, Mauro V, Aronica R, Al Ismail D, Ceccarelli G, Pinacchio C, d’Ettorre G, Mascellino MT, Mastroianni CM. Persistent systemic microbial translocation and intestinal damage during coronavirus disease-19. Front Immunol. 2021;14(12):708149. https://doi.org/10.3389/fimmu.2021.708149 .
doi: 10.3389/fimmu.2021.708149
Seethaler B, Basrai M, Neyrinck AM, Nazare JA, Walter J, Delzenne NM, Bischoff SC. Biomarkers for assessment of intestinal permeability in clinical practice. Am J Physiol Gastrointest Liver Physiol. 2021;321(1):G11–7. https://doi.org/10.1152/ajpgi.00113.2021 .
doi: 10.1152/ajpgi.00113.2021
pubmed: 34009040
Brenchley JM, Douek DC. Microbial translocation across the GI tract. Annu Rev Immunol. 2012;30:149–73. https://doi.org/10.1146/annurev-immunol-020711-075001 .
doi: 10.1146/annurev-immunol-020711-075001
pubmed: 22224779
pmcid: 3513328
Perkins MR, Bartha I, Timmer JK, Liebner JC, Wolinsky D, Günthard HF, Hauser C, Bernasconi E, Hoffmann M, Calmy A, Battegay M, Telenti A, Douek DC, Fellay J. The interplay between host genetic variation, viral replication, and microbial translocation in untreated HIV-infected individuals. J Infect Dis. 2015;212(4):578–84. https://doi.org/10.1093/infdis/jiv089 .
doi: 10.1093/infdis/jiv089
pubmed: 25701868
pmcid: 4539895
Oliva A, Cammisotto V, Cangemi R, Ferro D, Miele MC, De Angelis M, Cancelli F, Pignatelli P, Venditti M, Pugliese F, Mastroianni CM, Violi F. Low-grade endotoxemia and thrombosis in COVID-19. Clin Transl Gastroenterol. 2021;12(6):e00348. https://doi.org/10.14309/ctg.0000000000000348 .
doi: 10.14309/ctg.0000000000000348
pubmed: 34092777
pmcid: 8183715
Ciacci P, Paraninfi A, Orlando F, Rella S, Maggio E, Oliva A, Cangemi R, Carnevale R, Bartimoccia S, Cammisotto V, D’Amico A, Magna A, Nocella C, Mastroianni CM, Pignatelli P, Violi F, Loffredo L. Endothelial dysfunction, oxidative stress and low-grade endotoxemia in COVID-19 patients hospitalised in medical wards. Microvasc Res. 2023;149:104557. https://doi.org/10.1016/j.mvr.2023.104557 .
doi: 10.1016/j.mvr.2023.104557
pubmed: 37268038
pmcid: 10232918
Duarte MJ, Tien PC, Kardashian A, Ma Y, Hunt P, Kuniholm MH, Adimora AA, Fischl MA, French AL, Topper E, Konkle-Parker D, Minkoff H, Ofotokun I, Plankey M, Sharma A, Price JC. Microbial translocation and gut damage are associated with an elevated fast score in women living with and without HIV. Open Forum Infect Dis. 2024;11(5):187. https://doi.org/10.1093/ofid/ofae187 .
doi: 10.1093/ofid/ofae187
Cangemi R, Carnevale R, Nocella C, Calvieri C, Bartimoccia S, Frati G, Pignatelli P, Picchio V, Violi F. Low-grade endotoxemia is associated with cardiovascular events in community-acquired pneumonia. J Infect. 2024;88(2):89–94. https://doi.org/10.1016/j.jinf.2023.11.010 .
doi: 10.1016/j.jinf.2023.11.010
pubmed: 38000675
Juanola O, Francés R, Caparrós E. Exploring the relationship between liver disease, bacterial translocation, and dysbiosis: unveiling the gut-liver axis. Visc Med. 2024;40(1):12–9. https://doi.org/10.1159/000535962 .
doi: 10.1159/000535962
pubmed: 38312368
Blöbaum L, Witkowski M, Wegner M, Lammel S, Schencke PA, Jakobs K, Puccini M, Reißner D, Steffens D, Landmesser U, Rauch U, Friebel J. Intestinal barrier dysfunction and microbial translocation in patients with first-diagnosed atrial fibrillation. Biomedicines. 2023;11(1):176. https://doi.org/10.3390/biomedicines11010176 .
doi: 10.3390/biomedicines11010176
pubmed: 36672684
pmcid: 9856173
Violi F, Nocella C, Bartimoccia S, Castellani V, Carnevale R, Pignatelli P, Cammisotto V. Gut dysbiosis-derived low-grade endotoxemia: a common basis for liver and cardiovascular disease. Kardiol Pol. 2023;81(6):563–71. https://doi.org/10.33963/KP.a2023.0115 .
doi: 10.33963/KP.a2023.0115
pubmed: 37191190
Violi F, Nocella C. Editorial: gut permeability-related endotoxemia and cardiovascular disease: a new clinical challenge. Front Cardiovasc Med. 2023;21(10):1118625. https://doi.org/10.3389/fcvm.2023.1118625 .
doi: 10.3389/fcvm.2023.1118625
Fasano A. Intestinal permeability and its regulation by zonulin: diagnostic and therapeutic implications. Clin Gastroenterol Hepatol. 2012;10:1096–100.
doi: 10.1016/j.cgh.2012.08.012
pubmed: 22902773
pmcid: 3458511
Gajda AM, Storch J. Enterocyte fatty acid-binding proteins (FABPs): different functions of liver and intestinal FABPs in the intestine. Prostaglandins Leukot Essent Fatty Acids. 2015;93:9–16. https://doi.org/10.1016/j.plefa.2014.10.001 .
doi: 10.1016/j.plefa.2014.10.001
pubmed: 25458898
Mainous MR, Tso P, Berg RD, Deitch EA. Studies of the route, magnitude, and time course of bacterial translocation in a model of systemic inflammation. Arch Surg. 1991;126:33–7.
doi: 10.1001/archsurg.1991.01410250037005
pubmed: 1824677
Page MJ, Kell DB, Pretorius E. The role of lipopolysaccharide-induced cell signalling in chronic inflammation. Chronic Stress (Thousand Oaks). 2022;8(6):24705470221076390. https://doi.org/10.1177/24705470221076390 .
doi: 10.1177/24705470221076390
Stec A, Maciejewska M, Zaremba M, Paralusz-Stec K, Michalska M, Rudnicka L, Sikora M. The clinical significance of serum biomarkers of the intestinal barrier in systemic sclerosis: a cross-sectional study. J Pers Med. 2023;13(4):678. https://doi.org/10.3390/jpm13040678 .
doi: 10.3390/jpm13040678
pubmed: 37109064
pmcid: 10141873
van den Hoogen F, Khanna D, Fransen J, Johnson SR, Baron M, Tyndall A, Matucci-Cerinic M, Naden RP, Medsger TA Jr, Carreira PE, Riemekasten G, Clements PJ, Denton CP, Distler O, Allanore Y, Furst DE, Gabrielli A, Mayes MD, van Laar JM, Seibold JR, Czirjak L, Steen VD, Inanc M, Kowal-Bielecka O, Müller-Ladner U, Valentini G, Veale DJ, Vonk MC, Walker UA, Chung L, Collier DH, Ellen Csuka M, Fessler BJ, Guiducci S, Herrick A, Hsu VM, Jimenez S, Kahaleh B, Merkel PA, Sierakowski S, Silver RM, Simms RW, Varga J, Pope JE. 2013 classification criteria for systemic sclerosis: an American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 2013;72(11):1747–55. https://doi.org/10.1136/annrheumdis-2013-204424 .
doi: 10.1136/annrheumdis-2013-204424
pubmed: 24092682
LeRoy EC, Black C, Fleischmajer R, et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J Rheumatol. 1988;15:202–5.
pubmed: 3361530
Valentini G, Iudici M, Walker UA, et al. The European scleroderma trials and research group (EUSTAR) task force for the development of revised activity criteria for systemic sclerosis: derivation and validation of a preliminarily revised EUSTAR activity index. Ann Rheum Dis. 2017;76:270–6. https://doi.org/10.1136/annrheumdis-2016-209768 .
doi: 10.1136/annrheumdis-2016-209768
pubmed: 27621285
Medsger TA Jr, Silman AJ, Steen VD, et al. A disease severity scale for systemic sclerosis: development and testing. J Rheumatol. 1999;26:2159–67.
pubmed: 10529133
Cutolo M, Matucci CM. Nailfold capillaroscopy and classification criteria for systemic sclerosis. Clin Exp Rheumatol. 2007;25:663–5.
pubmed: 18078610
Khanna D, Nagaraja V, Gladue H, Chey W, Pimentel M, Frech T. Measuring response in the gastrointestinal tract in systemic sclerosis. Curr Opin Rheumatol. 2013;25(6):700–6. https://doi.org/10.1097/01.bor.0000434668.32150.e5 .
doi: 10.1097/01.bor.0000434668.32150.e5
pubmed: 24047604
Maselli R, Oliva A, Badalamenti M, Galtieri PA, Belletrutti PJ, Spadaccini M, Nicoletti R, Finati E, Vetrano S, Fosso F, Correale C, Pellegatta G, Hassan C, Repici A. Single-dose versus short-course prophylactic antibiotics for peroral endoscopic myotomy: a randomized controlled trial. Gastrointest Endosc. 2021;94(5):922–9. https://doi.org/10.1016/j.gie.2021.05.045 .
doi: 10.1016/j.gie.2021.05.045
pubmed: 34119499
García-Collinot G, Madrigal-Santillán EO, Martínez-Bencomo MA, Carranza-Muleiro RA, Jara LJ, Vera-Lastra O, et al. Effectiveness of saccharomyces boulardii and metronidazole for small intestinal bacterial overgrowth in systemic sclerosis. Dig Dis Sci. 2020;65:1134–43.
doi: 10.1007/s10620-019-05830-0
pubmed: 31549334
Bellocchi C, Volkmann ER. Update on the gastrointestinal microbiome in systemic sclerosis. Curr Rheumatol Rep. 2018;20:49.
doi: 10.1007/s11926-018-0758-9
pubmed: 29943234
Volkmann ER, Chang Y-L, Barroso N, Furst DE, Clements PJ, Gornet AH, et al. Association of systemic sclerosis with a unique colonic microbial consortium. Arthritis Rheumatol. 2016;68:1483–92.
doi: 10.1002/art.39572
pubmed: 26749064
pmcid: 5561666
Plichta DR, Somani J, Pichaud M, Wallace ZS, Fernandes AD, Perugino CA, Lähdesmäki H, Stone JH, Vlamakis H, Chung DC, Khanna D, Pillai S, Xavier RJ. Congruent microbiome signatures in fibrosis-prone autoimmune diseases: IgG4-related disease and systemic sclerosis. Genome Med. 2021;13(1):35. https://doi.org/10.1186/s13073-021-00853-7 .
doi: 10.1186/s13073-021-00853-7
pubmed: 33648559
pmcid: 7919092
Rosato E, Gigante A, Pellicano C, Villa A, Iannazzo F, Alunni Fegatelli D, Muscaritoli M. Symptoms related to gastrointestinal tract involvement and low muscularity in systemic sclerosis. Clin Rheumatol. 2022;41(6):1687–96. https://doi.org/10.1007/s10067-022-06059-5 .
doi: 10.1007/s10067-022-06059-5
pubmed: 35149929
pmcid: 9119878
Rosato E, Gigante A, Gasperini ML, Proietti L, Muscaritoli M. Assessing malnutrition in systemic sclerosis with global leadership initiative on malnutrition and European society of clinical nutrition and metabolism criteria. JPEN J Parenter Enteral Nutr. 2021;45(3):618–24. https://doi.org/10.1002/jpen.1872 .
doi: 10.1002/jpen.1872
pubmed: 32384169
Sakkas LI, Simopoulou T, Daoussis D, Liossis SN, Potamianos S. Intestinal involvement in systemic sclerosis: a clinical review. Dig Dis Sci. 2018;63(4):834–44. https://doi.org/10.1007/s10620-018-4977-8 .
doi: 10.1007/s10620-018-4977-8
pubmed: 29464583